CN111728975A - 用于减少运动损伤和促进运动损伤修复的组合物 - Google Patents
用于减少运动损伤和促进运动损伤修复的组合物 Download PDFInfo
- Publication number
- CN111728975A CN111728975A CN202010772579.9A CN202010772579A CN111728975A CN 111728975 A CN111728975 A CN 111728975A CN 202010772579 A CN202010772579 A CN 202010772579A CN 111728975 A CN111728975 A CN 111728975A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- stirring
- polyvinyl alcohol
- composition
- borneol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 208000025978 Athletic injury Diseases 0.000 title claims abstract description 26
- 230000008439 repair process Effects 0.000 title claims abstract description 17
- 230000001737 promoting effect Effects 0.000 title claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 55
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 29
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 29
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims abstract description 29
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 22
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 22
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229940116229 borneol Drugs 0.000 claims abstract description 22
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000008213 purified water Substances 0.000 claims abstract description 20
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims abstract description 16
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 16
- 235000011187 glycerol Nutrition 0.000 claims abstract description 16
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 16
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 16
- 235000011069 sorbitan monooleate Nutrition 0.000 claims abstract description 16
- 239000001593 sorbitan monooleate Substances 0.000 claims abstract description 16
- 229940035049 sorbitan monooleate Drugs 0.000 claims abstract description 16
- GNAYMQJAWJVZJT-UHFFFAOYSA-N 3-(5-phenylsulfanylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C(C=1)=CN=CC=1SC1=CC=CC=C1 GNAYMQJAWJVZJT-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 239000007888 film coating Substances 0.000 claims abstract description 13
- 238000009501 film coating Methods 0.000 claims abstract description 13
- 229960005150 glycerol Drugs 0.000 claims abstract description 6
- 229940068984 polyvinyl alcohol Drugs 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims description 28
- 239000011259 mixed solution Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 238000000227 grinding Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- 230000008961 swelling Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 206010041738 Sports injury Diseases 0.000 abstract description 14
- 230000006378 damage Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001179 synovial fluid Anatomy 0.000 description 3
- 208000034656 Contusions Diseases 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000009692 acute damage Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 240000000572 Blumea balsamifera Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- SQFDQLBYJKFDDO-UHFFFAOYSA-K merbromin Chemical compound [Na+].[Na+].C=12C=C(Br)C(=O)C=C2OC=2C([Hg]O)=C([O-])C(Br)=CC=2C=1C1=CC=CC=C1C([O-])=O SQFDQLBYJKFDDO-UHFFFAOYSA-K 0.000 description 1
- 229940008716 mercurochrome Drugs 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- ZSSCVXMAHNMCPY-UHFFFAOYSA-N propanenitrile 2,2,2-trifluoroacetic acid Chemical compound CCC#N.OC(=O)C(F)(F)F ZSSCVXMAHNMCPY-UHFFFAOYSA-N 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种用于减少运动损伤和促进运动损伤修复的组合物,其特征在于,所述组合物是由3‑[5‑(苯硫基)吡啶‑3‑基]‑3‑[4‑(7H‑吡咯并[2,3‑d]嘧啶‑4‑基)‑1H‑吡唑‑1‑基]丙腈三氟乙酸盐、冰片、聚乙烯醇、脱水山梨糖醇单油酸酯、甘油、吐温80、依地酸二钠、乙醇和纯化水制成的涂膜剂。本发明所述的组合物具有优异的减少运动损伤和促进其修复的功能。
Description
技术领域
本发明涉及医药技术领域,具体涉及一种用于减少运动损伤和促进运动损伤修复的组合物。
背景技术
随着人们的生活水平和健康意识的不断提高,越来越多的人认识到运动对于保持身体健康的重要性,并积极参与其中。但是,由于运动前不做准备活动或准备活动不充分,训练水平不够,身体状态不佳,灵活性和柔韧性差,动作不正确,缺乏自我保护能力等原因,人们在运动过程中或运动之后经常会发生各种各样的损伤,如擦伤、扭伤、挫伤、关节疼痛、跟腱撕裂等,甚至可发生出血、脱臼、骨折等严重损伤。
运动损伤(Athletic Injuries)指的就是运动过程中以及运动之后发生的由于机体受到机械性和物理性方面的因素的刺激而产生的人体的器官或组织解剖结构的破坏和生理功能的紊乱。一般而言运动损伤以急性损伤较常见,急性损伤治疗不当或过早参加训练等原因可转化为慢性损伤,从而严重影响患者的生活质量。
目前,运动损伤的主要护理方式包括冷敷、热敷等物理处理,用消毒酒精、碘酒、红药水或紫药水等外用消毒剂消毒,用纱布覆盖和用绷带包扎,使用云南白药、红花油等药物处理。但是,这些传统的方法起效慢,对运动损伤的恢复效应不明显,对伤口的刺激性较大,故存在一些局限性。因此,如何克服现有的运动损伤的护理的方式的缺点,从而提供一种减少运动损伤和促进运动损伤修复的组合物,成为了本领域技术人员旨在解决的问题。
发明内容
本发明所要解决的技术问题是克服现有技术的不足,提供一种用于减少运动损伤和促进运动损伤修复的组合物。
本发明所采用的技术方案为:一种用于减少运动损伤和促进运动损伤修复的组合物,其特征在于,所述组合物是由3-[5-(苯硫基)吡啶-3-基]-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈三氟乙酸盐(在实施例部分中简称为“本发明的化合物”)、冰片、聚乙烯醇、脱水山梨糖醇单油酸酯、甘油、吐温80、依地酸二钠、乙醇和纯化水制成的涂膜剂。该组合物具有优异的减少运动损伤和促进其修复的功能。
所谓“涂膜剂(Paints)”是指药物溶解或分散于含成膜材料(例如聚乙烯醇)的溶剂中,涂抹患处后形成薄膜的外用液体制剂。使用时,将涂膜剂涂于患处,有机溶剂迅速挥发,同时在患处形成薄膜,逐渐释放所含的药物,从而发挥治疗作用。
所述“聚乙烯醇”为醋酸乙烯在甲醇溶剂中进行缩合反应,生成聚醋酸乙烯,最后与甲醇发生醇解反应得到的高分子材料,呈白色或黄白色粉末状。聚乙烯醇有PVA05-88、PVA17-88等多种规格。PVA05-88的平均聚合度为500-600(分子量为22000-26400),水溶性较大,柔韧性稍差,PVA17-88的平均聚合度为1700-1800(分子量为74800-79200),水溶性较小,柔韧性较好。两者以适当比例配合使用,能够综合两种规格的聚乙烯醇的优点,并弥补其不足。
在一个方面中,所述3-[5-(苯硫基)吡啶-3-基]-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈三氟乙酸盐、冰片、聚乙烯醇、脱水山梨糖醇单油酸酯、甘油、吐温80、依地酸二钠和乙醇的重量比为5-20:3-12:15-60:2.5-10:2.5-10:1-4:0.5-2:200-800。
优选地,所述3-[5-(苯硫基)吡啶-3-基]-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈三氟乙酸盐、冰片、聚乙烯醇、脱水山梨糖醇单油酸酯、甘油、吐温80、依地酸二钠和乙醇的重量比为10:6:30:5:5:2:1:400。
优选地,所述聚乙烯醇是PVA05-88与PVA17-88的重量比为1:3的混合物。
在一个方面中,所述组合物的制备方法包括如下步骤:
1)将3-[5-(苯硫基)吡啶-3-基]-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈三氟乙酸盐和冰片研成细粉,加入少量乙醇(例如,占乙醇总重量30-50%的乙醇)中并搅拌均匀;
2)将脱水山梨糖醇单油酸酯、吐温80、依地酸二钠、甘油和余量的乙醇合并,并搅拌均匀;
3)取聚乙烯醇,加入5-7倍量的纯净水中浸泡溶胀,然后置于85-95℃水浴上加热溶解,在搅拌下依次加入步骤1)和步骤2)得到的混合物,加入完毕后将得到的混合溶液趁热用80目筛网过滤,并自然冷却;和
4)加入纯净水至足量,搅匀,即得。
在一个方面中,本发明还提供了一种用于制备本发明所述的用于减少运动损伤和促进运动损伤修复的组合物的方法,其特征在于该方法包括如下步骤:
1)将3-[5-(苯硫基)吡啶-3-基]-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈三氟乙酸盐和冰片研成细粉,加入少量乙醇(例如,占乙醇总重量30-50%的乙醇)中并搅拌均匀;
2)将脱水山梨糖醇单油酸酯、吐温80、依地酸二钠、甘油和余量的乙醇合并,并搅拌均匀;
3)取聚乙烯醇,加入5-7倍量的纯净水中浸泡溶胀,然后置于85-95℃水浴上加热溶解,在搅拌下依次加入步骤1)和步骤2)得到的混合物,加入完毕后将得到的混合溶液趁热用80目筛网过滤,并自然冷却;和
4)加入纯净水至足量,搅匀,即得。
本发明所述的用于减少运动损伤和促进运动损伤修复的组合物中的活性成分之一是3-[5-(苯硫基)吡啶-3-基]-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈三氟乙酸盐,其结构式如下:
3-[5-(苯硫基)吡啶-3-基]-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈三氟乙酸盐最初作为用于治疗与两面神激酶(Janus kinase)的活性相关的疾病,例如免疫相关的疾病、皮肤病、脊髓增生性疾病、癌症及其它疾病的两面神激酶抑制剂化合物公开于国际专利公开号WO2007/070514A1(参见实施例488)中。
冰片,又名龙脑,是由樟科植物龙脑樟枝叶或菊科艾纳香茎叶经水蒸汽蒸馏和重结晶而得或者用松节油经一系列化学方法工艺而得的无色透明或白色半透明的片状松脆结晶。冰片气清香,味辛、凉,具有抗菌消炎,明目退翳的作用。
发明人意外地发现,将并不已知用于减少运动损伤和促进运动损伤修复的3-[5-(苯硫基)吡啶-3-基]-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈三氟乙酸盐和冰片配伍,佐以聚乙烯醇、脱水山梨糖醇单油酸酯、甘油、吐温80、依地酸二钠、乙醇和纯化水等辅料制成的涂膜剂具有优异的减少运动损伤和促进其修复的功能。
为了进一步阐明本发明的精神和要旨,下面将结合具体实施方式对本发明的优选实施方案及其效果进行描述。但是,应理解这些优选实施方案的描述只是用于进一步举例说明本发明的特征和优点,而绝非对本发明的权利要求构成任何限制。
具体实施方式
实施例1
涂膜剂1
【配方】
注:所述聚乙烯醇是PVA05-88与PVA17-88的重量比为1:3的混合物。
【制备方法】
1)将本发明的化合物和冰片研成细粉,加入160g乙醇中并搅拌均匀;
2)将脱水山梨糖醇单油酸酯、吐温80、依地酸二钠、甘油和余量的乙醇合并,并搅拌均匀;
3)取聚乙烯醇,加入180g纯净水中浸泡溶胀,然后置于90℃水浴上加热溶解,在搅拌下依次加入步骤1)和步骤2)得到的混合物,加入完毕后将得到的混合溶液趁热用80目筛网过滤,并自然冷却;和
4)加入纯净水至足量,搅匀,即得。
实施例2
涂膜剂2
【配方】
注:所述聚乙烯醇是PVA05-88与PVA17-88的重量比为1:3的混合物。
【制备方法】
1)将本发明的化合物和冰片研成细粉,加入160g乙醇中并搅拌均匀;
2)将脱水山梨糖醇单油酸酯、吐温80、依地酸二钠、甘油和余量的乙醇合并,并搅拌均匀;
3)取聚乙烯醇,加入180g纯净水中浸泡溶胀,然后置于90℃水浴上加热溶解,在搅拌下依次加入步骤1)和步骤2)得到的混合物,加入完毕后将得到的混合溶液趁热用80目筛网过滤,并自然冷却;和
4)加入纯净水至足量,搅匀,即得。
实施例3
涂膜剂3
【配方】
注:所述聚乙烯醇是PVA05-88与PVA17-88的重量比为1:3的混合物。
【制备方法】
1)将本发明的化合物和冰片研成细粉,加入160g乙醇中并搅拌均匀;
2)将脱水山梨糖醇单油酸酯、吐温80、依地酸二钠、甘油和余量的乙醇合并,并搅拌均匀;
3)取聚乙烯醇,加入180g纯净水中浸泡溶胀,然后置于90℃水浴上加热溶解,在搅拌下依次加入步骤1)和步骤2)得到的混合物,加入完毕后将得到的混合溶液趁热用80目筛网过滤,并自然冷却;和
4)加入纯净水至足量,搅匀,即得。
对比例1
采用与实施例2类似的方法制备涂膜剂,区别在于省略掉本发明的化合物成分。
对比例2
采用与实施例2类似的方法制备涂膜剂,区别在于省略掉冰片成分。
实验例
本实验例的目的是考察根据本发明的方法制备得到的涂膜剂是否具有优异的减少运动损伤和促进其修复的功能。
1、实验方法
本实验采用10周龄左右的体重为280g±20g的Wistar大鼠。将动物饲养在23℃室温、50%相对湿度和12小时光照/12小时黑暗条件下适应环境两天。动物可自由摄入清洁的食物和饮用水。
实验当日,将体重差异无统计学意义的Wistar大鼠随机分为4组,即空白组、实施例2组、对比例1组和对比例2组,每组8只大鼠。将所有大鼠进行跑台实验(ZH-PT型动物实验跑台,购自于安徽正华生物仪器设备有限公司),其中跑台的倾角设置为-15度,速度设置为20米/分钟。将每只大鼠每天训练1小时,连续训练8周。实验结束后,将供试品每天1次地施用于大鼠的四肢,连续施用3天,其中空白组施用纯净水,其余各组分别给予所示的涂膜剂。末次给药后24小时,将大鼠断头处死并取新鲜血液,测定血清肌酸激酶和关节液中白介素1β的含量。
2、实验结果
本实验的结果参见下表1。
表1各个实验组的大鼠的血清肌酸激酶和关节液中白介素1β的含量
以上数值为各实验组的结果的平均值。使用Student t检验(Student's t test)考察各组结果之间的差异的统计学上的显著性,结果显示对于以上两种参数而言,实施例2组与空白组、对比例1组和对比例2组之间的差异具有统计学意义(p值<0.05)。
5、讨论
以上结果验证了发明人的意外发现:将并不已知用于减少运动损伤和促进运动损伤修复的3-[5-(苯硫基)吡啶-3-基]-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈三氟乙酸盐和冰片配伍,佐以聚乙烯醇、脱水山梨糖醇单油酸酯、甘油、吐温80、依地酸二钠、乙醇和纯化水等辅料制成的涂膜剂,能够显著降低持续一段时间的高强度剧烈运动后大鼠的血清肌酸激酶和关节液中白介素1β的含量,且这一作用优于省略掉3-[5-(苯硫基)吡啶-3-基]-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈三氟乙酸盐的对比例1组和省略掉冰片的对比例2组。以上结果提示,根据本发明的方法制备得到的涂膜剂能够减少运动引起的骨骼肌损伤,并缩短骨关节损伤的恢复期,即具有优异的减少运动损伤和促进其修复的功能。
Claims (6)
1.一种用于减少运动损伤和促进运动损伤修复的组合物,其特征在于,所述组合物是由3-[5-(苯硫基)吡啶-3-基]-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈三氟乙酸盐、冰片、聚乙烯醇、脱水山梨糖醇单油酸酯、甘油、吐温80、依地酸二钠、乙醇和纯化水制成的涂膜剂。
2.根据权利要求1所述的组合物,其特征在于所述3-[5-(苯硫基)吡啶-3-基]-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈三氟乙酸盐、冰片、聚乙烯醇、脱水山梨糖醇单油酸酯、甘油、吐温80、依地酸二钠和乙醇的重量比为5-20:3-12:15-60:2.5-10:2.5-10:1-4:0.5-2:200-800。
3.根据权利要求2所述的组合物,其特征在于所述3-[5-(苯硫基)吡啶-3-基]-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈三氟乙酸盐、冰片、聚乙烯醇、脱水山梨糖醇单油酸酯、甘油、吐温80、依地酸二钠和乙醇的重量比为10:6:30:5:5:2:1:400。
4.根据权利要求1所述的组合物,其特征在于所述聚乙烯醇是PVA05-88与PVA17-88的重量比为1:3的混合物。
5.根据权利要求1-4中任一项所述的组合物,其特征在于所述组合物的制备方法包括如下步骤:
1)将3-[5-(苯硫基)吡啶-3-基]-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈三氟乙酸盐和冰片研成细粉,加入少量乙醇中并搅拌均匀;
2)将脱水山梨糖醇单油酸酯、吐温80、依地酸二钠、甘油和余量的乙醇合并,并搅拌均匀;
3)取聚乙烯醇,加入5-7倍量的纯净水中浸泡溶胀,然后置于85-95℃水浴上加热溶解,在搅拌下依次加入步骤1)和步骤2)得到的混合物,加入完毕后将得到的混合溶液趁热用80目筛网过滤,并自然冷却;和
4)加入纯净水至足量,搅匀,即得。
6.一种用于制备根据权利要求1-5中任一项所述的组合物的方法,其特征在于该方法包括如下步骤:
1)将3-[5-(苯硫基)吡啶-3-基]-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈三氟乙酸盐和冰片研成细粉,加入少量乙醇中并搅拌均匀;
2)将脱水山梨糖醇单油酸酯、吐温80、依地酸二钠、甘油和余量的乙醇合并,并搅拌均匀;
3)取聚乙烯醇,加入5-7倍量的纯净水中浸泡溶胀,然后置于85-95℃水浴上加热溶解,在搅拌下依次加入步骤1)和步骤2)得到的混合物,加入完毕后将得到的混合溶液趁热用80目筛网过滤,并自然冷却;和
4)加入纯净水至足量,搅匀,即得。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020101161256 | 2020-02-25 | ||
CN202010116125 | 2020-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111728975A true CN111728975A (zh) | 2020-10-02 |
Family
ID=72657134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010772579.9A Pending CN111728975A (zh) | 2020-02-25 | 2020-08-04 | 用于减少运动损伤和促进运动损伤修复的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111728975A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3107895A1 (de) * | 1981-03-02 | 1982-10-07 | Schweiger Hubert | Diterpene in synergistisch wirkenden kombinationen mit (alpha)-ketosaeuren und deren estern und verwendung dieser pflanzlichen wirkstoffkombinationen als bioaktive mittel in arznei- und kosmetischen mitteln |
US20130137681A1 (en) * | 2005-12-13 | 2013-05-30 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
CN103214484A (zh) * | 2005-12-13 | 2013-07-24 | 因塞特公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
CN106902105A (zh) * | 2017-03-13 | 2017-06-30 | 牡丹江医学院 | 一种用于运动损伤保护的方法 |
CN110664756A (zh) * | 2019-10-09 | 2020-01-10 | 吉林大学 | 一种小儿外伤喷雾剂及其制备方法 |
-
2020
- 2020-08-04 CN CN202010772579.9A patent/CN111728975A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3107895A1 (de) * | 1981-03-02 | 1982-10-07 | Schweiger Hubert | Diterpene in synergistisch wirkenden kombinationen mit (alpha)-ketosaeuren und deren estern und verwendung dieser pflanzlichen wirkstoffkombinationen als bioaktive mittel in arznei- und kosmetischen mitteln |
US20130137681A1 (en) * | 2005-12-13 | 2013-05-30 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
CN103214484A (zh) * | 2005-12-13 | 2013-07-24 | 因塞特公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
CN106902105A (zh) * | 2017-03-13 | 2017-06-30 | 牡丹江医学院 | 一种用于运动损伤保护的方法 |
CN110664756A (zh) * | 2019-10-09 | 2020-01-10 | 吉林大学 | 一种小儿外伤喷雾剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10485826B2 (en) | Pharmaceutical formula for the treatment and/or prevention of arthritis and its manufacture | |
MX2007014856A (es) | Composicion de factor de crecimiento epidermico, un proceso para el mismo y su aplicacion. | |
TWI830696B (zh) | 抑制肌纖維變性用組成物 | |
CN111728975A (zh) | 用于减少运动损伤和促进运动损伤修复的组合物 | |
RU2381810C1 (ru) | Гель-бальзам, обладающий ранозаживляющим действием | |
CN104288278B (zh) | 美洲大蠊与地榆的联合用药用途 | |
CN1895275A (zh) | 一种小牛血去蛋白提取物凝胶剂 | |
RU2209074C2 (ru) | Состав для лечения ожогов | |
CN105251044A (zh) | 一种聚羟基乙酸抗感染手术缝合线及制法 | |
CN110772632A (zh) | 神经导向因子semaphorin 3a在制备治疗骨关节炎药物中的用途 | |
Khokhlenkova | Prospects of using biopolymeric films in medicine and pharmacy | |
RU2802235C1 (ru) | Мазь на основе пчелиного воска для лечения болезней кожи животных | |
RU2197981C1 (ru) | Ранозаживляющее средство "зайда" | |
RU2146924C1 (ru) | Средство, стимулирующее процессы заживления гнойных ран | |
RU2235550C2 (ru) | Лекарственное средство бионормализующего действия и способ его получения | |
RU2355411C1 (ru) | Ранозаживляющая мазь | |
WO2021179319A1 (zh) | 一种含水解硫酸软骨素的用于防治骨关节病的组合物 | |
CN116983285A (zh) | 一种用于风湿痹痛的缓释贴剂及其制备方法 | |
CN116785229A (zh) | 一种伤口护理软膏及其制备方法 | |
CA2745579A1 (en) | Thick pine needle extract composition for capsulation | |
RU2453321C1 (ru) | Препарат для лечения животных с противовоспалительным и антибактериальным действиями | |
RU2304429C2 (ru) | Мазь для лечения дегенеративно-дистрофических заболеваний опорно-двигательной системы | |
CN101190178B (zh) | 抗病毒局部成膜凝胶组合物 | |
CN108434159A (zh) | N-乙酰-d-氨基葡萄糖在制备治疗糖尿病并发症的药物中的应用及药物、保健品 | |
RU2070409C1 (ru) | Препарат для лечения мастита у лактирующих животных |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201002 |
|
RJ01 | Rejection of invention patent application after publication |